Business
Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic
About this update from Praxis Precision Medicines, Inc.
[{"type":"text","content":"BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will present data from two of its clinical-stage epilepsy programs at the upcoming 35th International Epilepsy Congress (IEC), to be held on September 2-6, 2023 in Dublin, Ireland. “There remains a great unmet need in epilepsy for anti-seizure medications that restore quality of life to patients and their families, and we are committed to developing best-in-class treatment options for both rare and prevalent epilepsies,” said Marcio Souza, president and chief executive officer of Praxis. “Data from our Phase 1 study of PRAX-628 for focal epilepsy support a potentially best-in-class safety profile that could address the limitations of existing therapies, such as poor tolerability and dose-limiting titration requirements. We look forward to presenting data from this program along with data from our PRAX-562 program for children with SCN2A and SCN8A developmental and epileptic encephalopathies.” Presentation Details: PRAX-628: A Next Generation Functionally Selective Small Molecule with Potent Anticonvulsant Activity Session Date/Time: Sunday, September 3, 1:00 p.m. – 3:30 p.m. ISTPoster Session: Drug TherapyPoster number: P031 PRAX-562 is a Well-Tolerated, Next Generation Anti-Seizure Small Molecule with Broad Anticonvulsant Activity in Multiple DEE Mouse Models Session Date/Time: Sunday, September 3, 1:00 p.m. – 3:30 p.m. ISTPoster Session: Pediatric EpileptologyPoster number: P095 PRAX-562-101: A First-in-Human Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of PRAX-562 in Healthy Volunteers Session Date/Time: Monday, September 4, 7:00 p.m. – 7:40 p.m. ISTPoster Session: Pediatric Epileptology & MixedPoster number: 408 PRAX-562-102: A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRAX-562 in Healthy Volunteers Session Date/Time: Monday, September 4, 7:00 p.m. – 7:40 p.m. ISTPoster Session: Pediatric Epileptology & MixedPoster number: 409 Safety, Tolerability and Pharmacokinetic Findings from a First-in-Human, Randomized, Double-Bli...